Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two Part First-in-human Phase I Study (With Expanded Cohorts) With the Antibody-drug Conjugate SYD985 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Locally Advanced or Metastatic Solid Tumors

Next Previous
Search
Trial Profile

A Two Part First-in-human Phase I Study (With Expanded Cohorts) With the Antibody-drug Conjugate SYD985 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Locally Advanced or Metastatic Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-duocarmazine (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Endometrial cancer; Gastric cancer; HER2 positive breast cancer; Oesophageal cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Byondis; Synthon

    • Most Recent Events

    • 13 Nov 2019 Status changed from active, no longer recruiting to completed.
    • 27 Jun 2019 Results assessing the safety, pharmacokinetics, and preliminary antitumour activity of trastuzumab duocarmazine in patients with locally advanced or metastatic solid tumours published in the Lancet Oncology
    • 11 Feb 2019 Planned End Date changed from 1 Mar 2019 to 1 Oct 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top